Network pharmacology integrated molecular dynamics reveals the bioactive compounds and potential targets of *Tinospora crispa* Linn. as insulin sensitizer

**Abstract**

Insulin resistance is a metabolic disorder characterized by the decreased response to insulin in muscle, liver, and adipose cells. This condition remains a complex phenomenon that involves several genetic defects and environmental stresses. In the present study, we investigated the mechanism of known phytochemical constituents of *Tinospora crispa* and its interaction with insulin-resistant target proteins by using network pharmacology, molecular docking, and molecular dynamics (MD) simulation. Tinoscorside A, Makisterone C, Borapetoside A and B, and β-sitosterol consider the main phytoconstituents of *Tinospora crispa* by its binding with active sites of main protein targets of insulin resistance potential therapy. Moreover, Tinoscorside A was revealed from the docking analysis as the ligand that binds most strongly to the target protein, PI3K. This finding was strengthened by the results of MD simulation, which stated that the conformational stability of the ligand-protein complex was achieved at 15 ns and the formation of hydrogen bonds at the active site. In conclusion, *Tinospora crispa* is one of the promising therapeutic agent in type 2 diabetes mellitus management. Regulation in glucose homeostasis, adipolysis, cell proliferation, and antiapoptosis are predicted to be the critical mechanism of *Tinospora crispa* as an insulin sensitizer.

**Introduction**

Insulin resistance is a metabolic disorder characterized by the decreased response to insulin in muscle, liver, and adipose cells. The normal insulin levels are unable to control glucose, lipids, and energy homeostasis. This condition remains a complex phenomenon that involves several genetic defects and environmental stresses, such as obesity. A complete understanding is required to understand the entire itinerary and functional consequences of insulin resistance...
to develop a potent drug in diabetes management [1]. Furthermore, drug monotherapy is challenging to provide the desired effect in controlling blood glucose levels in type 2 diabetes patients. Combination therapy which has different mechanisms, is needed for maintaining the requirement of therapeutic management. However, this strategy meets some disadvantages regarding the increasing of drug side effects, toxicity, and interactions. Another alternative is the search for a drug molecule that selectively modulates different targets and improving the balance of efficacy and safety compared to single target agents [2].

This approach aligns with the paradigm that has begun to change in natural product drug discovery, the "herbal shotgun", which utilizes the synergy of multi constituents with varied targets [3]. Research on antidiabetic drugs from Tinospora crispa (T. crispa) are still using the "silver bullet" approach, which is oriented towards the single active principle with one target. As a result, the information obtained was not comprehensively explaining the activity of T. crispa, yet it was closer to the activity of specific metabolites contained in T. crispa [4–12]. Research on medicinal plants conducted by Wink et al. also supports the herbal shotgun approach. It was reported that the combination of metabolite compounds in the medicinal plant had a better effect than the single isolate of metabolite compound [13]. This fact requires more recent research using the herbal shotgun approach so that the activity of medicinal plants can be comprehensively reveal [3].

*T. crispa* as a multi-constituent preparation has not known its action mechanism in insulin sensitization activity. It needs to be explored more extensively using a comprehensive approach in silico prediction such as network pharmacology analysis. The current development of bioinformatics technology allows researchers to simultaneously predict the action mechanism of medicinal plant constituents as a multicomponent therapeutic activity. This study aims to find a significant therapeutic target in the pathogenesis of insulin resistance targeted by the active compound of T. crispa. The known therapeutic target of compounds contained in T. crispa was analyzed using network pharmacology to determine its potential activity as an insulin sensitizer. The most significant protein targets then verified its binding with T. crispa constituents by molecular docking and molecular dynamics to verify its interactions (Fig 1).

### Material and methods

**Constructing database of known *Tinospora crispa* chemical constituents**

Data of chemical constituents in *T. crispa* was acquired from former research related to *T. crispa* constituent identification [4–12]. Database constructing the 2D structure was made in sdf format were collected from PubChem, ChemSpider (http://www.chemspider.com/), or drawn using MarvinSketch (https://chemaxon.com/products/marvin) [14]. Each 2D structure then changed to a 3D structure using MarvinSketch and saved as PDB format [15]. The 2D structure was needed for druggability analysis in each component, besides the 3D structure for molecular docking analysis. Its compound’s drugability was predicted by the SwissADME database (http://www.swissadme.ch/), including its drug-likeness based on Lipinsky rules of five and its oral bioavailability prediction [16].

**Constructing a database of protein target involved in insulin resistance**

Target proteins related to insulin resistance were retrieved from DisGeNET, UniProt, OMIM, TTD, KEGG, and DrugBank database [17–21]. Data retrieval from DisGeNET were done with the keyword “Insulin resistance” (CUI: C0021655) in the diseases search engine column. The retrieved data was a summary of gene-disease associations that have been downloaded in xlsx format (80 genes). Data retrieval from UniProt was done using the human disease option in supporting data and input keyword "Diabetes mellitus, non-insulin-dependent” (DI-02060).
Data were downloaded in tab file format (23 genes). Data from both data sources were merging in Cytoscape 3.7.2 software (https://cytoscape.org/) using UniProt ID as their identity to eliminate double listed proteins [18, 22].

**Constructing target proteins of *Tinospora crispa* phytochemical constituents**

The simplified molecular-input line-entry specification (SMILES) information of 56 TC constituents was submitted in SWISS Target Prediction (http://www.swisstargetprediction.ch/) PharmMapper to obtain its target prediction. Only human (*Homo sapiens*) target protein was set in the data retrieval [23, 24]. Protein ID was aligned using UniProt ID to synchronize protein ID and eliminate double listed protein [18]. The aligned target proteins ID were arranged in excel format to be imported to Cytoscape 3.7.2, be visualized, and analyzed its degree of connectivity [22].

**Prediction of significance target protein related insulin resistant**

Protein-protein interaction (PPI) was generated by submitting all UniProt IDs of the proteins constructed from the previous step into the STRING database (https://string-db.org/) using
multiple proteins option [25]. *Homo sapiens* was set as the only organism, and the interaction score confidence was set at the highest confidence (0.900). PPI data is then downloaded in tsv format. Furthermore, the PPI network was analyzed using Cytoscape 3.7.2 software to discover the rank of significance protein based on the degree of connectivity score [22].

**Prediction of *Tinospora crispa* phytoconstituents target genes and their intersection on insulin resistant related target**

All the phytochemical *T. crispa* compounds were predicted its target by SwissTargetPrediction and PharmMapper [23, 24]. To comprehensively understand its molecular mechanism, all compound-target data were visualized by Cytoscape 3.7.2 to reveal the interaction network between compound-target. Furthermore, the network then merged with the PPI network to discover a new network, a compound-target network of *T. crispa* targeted to insulin resistance.

**Ligand and protein preparation for in silico molecular docking**

Molecular docking was conducted towards the significant proteins in insulin resistance pathogenesis and was targeted by constituents of *T. crispa* at once. Target proteins that meet the criteria were PIK3R1, PTPN1, PPARG, INSR, EGFR, TNF, and AKT2. The 3D structure of *T. crispa* constituents act as ligands (file type.pdb) were opened using AutoDock Tools 1.5.6 software (Molecular Graphics Laboratory, The Scripps Research Institute) [15]. Water molecules were removed, and chain contained active site was chosen. The chosen structure is then extracted from its native ligand. The 3D crystal structures of target proteins were selected from Protein Data Bank (PDB) (http://www.rcsb.org/pdb/) [26]. Protein structures with PDB accession number 3S2A were used for PIK3R1 target, 1LQF for PTPN1 target, 6O67 for PPARG target, 5E1S for INSR, 6D8E for EGFR target, 5MU8 for TNF target, and 5D0E for AKT2 target. All protein models were prepared by the addition of polar hydrogen and the addition of Gasteiger charges. Ligands were prepared with a torsion value less than 32. Both ligands and protein models were saved as a pdbqt file. Preparation steps were done using AutoDock Tools 1.5.6 software.

**Molecular docking**

Molecular docking was generated using AutoDock Vina (Molecular Graphics Laboratory, The Scripps Research Institute) for initial screening of all *T. crispa* constituents followed by AutoDock Tools 1.5.6 only for the top 3 constituents with the lowest binding energy [15, 27]. The ligands were set as rigid structures with an active site was set visually at the centre of the cavity docked by native ligand from each protein model. The grid box was adjusted at 40 x 40 x 40 Angstrom in x, y, and z-axis, respectively. Molecular docking was run in the Lamarckian Genetic Algorithm after validation. Redocking the native ligand with its protein in specific parameters with an RMSD value less than 2 Angstrom remains a valid docking parameter [28]. The results were shown in the value of its lowest binding energy (kcal/mol) calculated by total intermolecular energies, including hydrogen bonds energy, Van der Walls energy, desolvation energy, and electrostatic energy. The more negative energy was, the better ligand-protein binding [29]. The result of ligand-protein complexes was visualized using PyMOL (https://pymol.org/2/). The docking results were analyzed in LigPlot+ to evaluate the accurate binding interaction between ligands and proteins [30].

**Molecular dynamics simulation**

Molecular dynamics simulation was carried out using GROMACS (Groningen Machine for Chemical Simulation) software package [31]. Previously docked complex ligand-protein was
subjected to 24 ns dynamic simulations in explicit water model using CHARMM36 for the protein and CGenFF force field for the ligand [32, 33]. TIP3P model was used to represent solvation on water molecules using a periodic cubic box with 1.0 nm minimum distance from any atom in the protein to the walls of the cubic box [34]. The whole system was neutralized to pH 7 by adding counter ions, followed by energy minimization, heating and equilibration by running 100 ps of NVT (isothermal-isochoric) and NPT (isothermal-isobaric) ensemble. The production step was carried out at 300K and around 1 atmospheric pressure for 24 ns with a time step of 2 fs. Hydrogen bonds, root mean square deviation (RMSD) of protein (backbone and side chains), as well as root mean square fluctuation (RMSF) of amino acid residues were used to evaluate the ligand-protein interaction. The RMSD and RMSF were plotted using GRACE v5.1.25.

Results

Database of *Tinospora crispa* phytoconstituents

A total of 56 compounds were found in the literature related to *T. crispa*. 2D and 3D structures of all compounds were collected from PubChem, ChemSpider, or drawn using Marvin Sketch [14]. Its compounds druggability were predicted using SwissADME, including its drug-like-ness based on Lipinsky rules of five and its oral bioavailability prediction (Table 1) [16]. The molecular weight range from 135.13 to 714.71, with Adenine as the lightest molecule and Borapetoside H as the heaviest molecule. Predicted gastrointestinal absorption showed 34 of 56 compounds classified as highly absorbed in the GI tract. Drug likeness was assessed through the Lipinski Rules of Five, with 37 compounds meet the five criteria required by Lipinski, while 19 other compounds have violations of Lipinski’s rules of 1–3 violations.

SWISS target prediction and DisGeNET identified that 56 constituents of *T. crispa* were documented to have 5666 protein-specific targets [17, 23]. Those 5666 target proteins were then analyzed by Cytoscape 3.7.2 to find out its intersection with insulin-resistant target protein [22].

Protein-protein interaction networks related to insulin resistance

267 targets were documented to have relation to insulin resistance pathogenesis. All targets were identified its interaction using STRING database [25]. Those interactions construct a PPI network which is then assessed by Cytoscape 3.7.2 software for the degree of connectivity value. The analysis results were displayed in Fig 2 in white to green gradation. The higher the degree of a node (gene) in the network is marked with a darker green colour. The higher the degree value indicates that the protein has a more significant role in the pathogenesis of insulin resistance. The top degree ranks were INS, LEP, PI3K, PTPN1, PPARG, INSR, CAV1, EGFR, IRS2, TNF, and AKT2, respectively. The degree rating of the entire PPI network is shown in Fig 2. The exact degree value was shown in S1 Table.

Interaction of lead compounds of *Tinospora crispa* on insulin resistant related target proteins

We conducted the molecular docking strategy to prove the underlying interactions between *T. crispa* predicted active phytoconstituents to insulin resistance. Molecular docking was conducted on seven target proteins that meet the criteria of high connectivity value, targeted by *T. crispa* constituents and was involved in insulin resistance pathogenesis. Those targets were PI3K, PTPN1, PPARG, INSR, EGFR, TNF, and AKT2. The best docking interaction was PI3K with Tinoscorside A as a ligand (binding energy -11.64), as shown in Table 2. Its binding
| Molecule                              | Formula     | MW (Dalton) | GI abs | Lipinski |
|--------------------------------------|-------------|-------------|--------|----------|
| (-)-Secoisolariresinol               | C20H26O6    | 362.42      | High   | 0        |
| N-Acetylnornuciferine                | C20H21NO3   | 323.39      | High   | 0        |
| N-cis-Ferulloyltyramine              | C18H19NO4   | 313.35      | High   | 0        |
| N-Formylanonaine                     | C18H15NO3   | 293.32      | High   | 0        |
| N-trans-Ferulloyltyramine            | C18H19NO4   | 313.35      | High   | 0        |
| Tembetarine                          | C20H26NO4   | 344.42      | High   | 0        |
| Tinocorsi A                          | C30H37NO13  | 619.61      | Low    | 3        |
| (-)-Litcubinine                      | C18H20NO4   | 314.36      | High   | 0        |
| Borapetol A                          | C20H24O7    | 376.4       | High   | 0        |
| Borapetol B                          | C21H26O7    | 390.43      | High   | 0        |
| Borapetolside A                      | C26H34O12   | 538.54      | Low    | 2        |
| Borapetoside B                       | C27H36O12   | 552.57      | Low    | 2        |
| Borapetoside C                       | C27H36O11   | 536.57      | Low    | 2        |
| Borapetoside D                       | C33H46O16   | 698.71      | Low    | 3        |
| Borapetoside E                       | C27H36O11   | 536.57      | Low    | 2        |
| Borapetoside F                       | C27H34O11   | 534.55      | Low    | 2        |
| Cycloeucalenone                      | C30H48O     | 424.7       | Low    | 1        |
| Dihyrodiscretamin                    | C19H18NO4   | 324.35      | High   | 0        |
| Luteolin 4'-methyl ether 7-glucoside | C22H22O11   | 462.4       | Low    | 2        |
| Makisterone                          | C29H48O7    | 508.69      | Low    | 2        |
| N-acetylanonaine                     | C19H17NO3   | 307.34      | High   | 0        |
| N-acetylanornuciferine               | C20H21NO3   | 323.39      | High   | 0        |
| N-formylanonaine                     | C18H15NO3   | 293.32      | High   | 0        |
| N-formylaminobine 2-O-β-D-glucopyranoside | C24H29NO7 | 443.49      | High   | 0        |
| N-trans-cafeoyltyramine              | C17H17NO4   | 299.32      | High   | 0        |
| Paprazine                            | C17H17NO3   | 283.32      | High   | 0        |
| Rumphioside A                        | C27H36O13   | 568.57      | Low    | 2        |
| Rumphioside B                        | C28H38O13   | 582.59      | Low    | 2        |
| (-)-Litcubinine                      | C18H20NO4   | 340.56      | High   | 0        |
| Berberine                            | C20H29NO4   | 347.45      | High   | 0        |
| Beta sitosterol                      | C29H50O     | 414.71      | Low    | 1        |
| Uridine                              | C9H12N2O6   | 244.2       | Low    | 0        |
| Tyramine                             | C8H11NO     | 137.18      | High   | 0        |
| Tinocrispol A                        | C21H24O7    | 388.41      | High   | 0        |
| Syringin                             | C17H24O9    | 372.37      | Low    | 0        |
| Syringaresinol                       | C22H26O8    | 418.44      | High   | 0        |
| Stigmasterol                         | C29H48O     | 412.69      | Low    | 1        |
| Secoisolariresinol                   | C20H26O6    | 362.42      | High   | 0        |
| Salso linol                          | C10H13NO2   | 179.22      | High   | 0        |
| Palmatine                            | C21H22NO4   | 352.4       | High   | 0        |
| Rumphiol                             | C20H24O6    | 360.4       | High   | 0        |
| N-demethyl-N-formyldehydronuciferine | C19H17NO3   | 307.34      | High   | 0        |
| Magnoflorine                         | C20H24NO4   | 342.41      | High   | 0        |
| Lysicamine                           | C18H13NO3   | 291.3       | High   | 0        |
| Luteolin 4'-methyl ether 7-glucoside | C22H22O11   | 462.4       | Low    | 2        |
| Luteolin 4'-methyl ether 3'-glucoside| C22H22O11   | 462.4       | Low    | 2        |
| Jatrorrhizine                        | C20H20NO4   | 338.38      | High   | 0        |

(Continued)
The detailed docking scores of T. crispa targeted to 7 significance proteins were shown in S3 Table, and the docking sketch maps were shown in S1 Fig. The structures of the main constituents of T. crispa were shown in Fig 4.

Molecular dynamics simulation

To clarify the protein-ligand stability and protein structural flexibility between the docked complex of PI3K and Tinoscorside, we performed a 24 ns MD simulation using GROMACS.
software. Protein and ligand root-mean-square deviation (RMSD) information of C alpha and side chains of the complex are presented in Fig 5A. The root-mean-square fluctuation (RMSF) of amino acid residues are presented in Fig 5B. RMSD calculation shows that the complex has nearly constant RMSD since 15 ns MD production. The maximum RMSF of the C alpha atom is 2.5–3.0 nm, except the initial C alpha residue, which reaches 3.5 nm. Hydrogen bonds between protein and ligand were ranged from 1–7 bonds in each frame (Fig 5C). There were 20 hydrogen bonds formed between protein-ligand during the MD simulation. The amino acid residues involved in forming hydrogen bonds are Ala805, Ser806, Lys833, Asp841, Tyr867, Glu880, Val882, Thr887, Asp964, and Lys890. The representation of the complex after 24 ns MD simulation was performed in Fig 5D.

**Compound-target network**

To further discover the potential target and therapeutic pathway of *T. crispa* constituents in ameliorating insulin resistance, the targets of insulin resistance were merged with the target of *T. crispa* (Fig 6A). The compound-target network of *T. crispa* against insulin resistance was shown in Fig 6C. After the network merging using Cytoscape 3.7.2, 30 *T. crispa* constituents were reserved as the main active constituents in *T. crispa* treating insulin resistance. In addition, 22 targets were reserved as the main targets of TC in treating insulin resistance.

| Target protein | Compound       | Ki (nM) | The lowest binding energy (kcal/mol) |
|----------------|----------------|--------|-------------------------------------|
| PI3K           | Tinoscorside A | 2.94   | -11.64                              |
| INSR           | Tinoscorside A | 4.19   | -11.43                              |
| AKT2           | Makisterone C  | 5.17   | -11.3                               |
| PPARG          | Borapetoside A | 51.96  | -9.94                               |
| EGFR           | Tinoscorside A | 191.99 | -9.16                               |
| PTPN1          | Beta sitosterol| 453.59 | -8.65                               |
| TNF            | Borapetoside B | 1.62x10³ | -7.90                            |

Table 2. Docking scores of the lowest ligand-protein binding energy of *T. crispa* constituents and significant proteins in insulin resistance.
Fig 4. Structure of active constituents prediction of *T. crispa* as insulin sensitizer. (A) Tinoscorside A (B) Makisterone C (C) Borapetoside A (D) β Sitosterol (E) Borapetoside B. All structures were drawn using MarvinSketch based on the previous studies [6].

https://doi.org/10.1371/journal.pone.0251837.g004

Fig 5. Molecular dynamics (MD) simulation analysis of Tinoscorside A with PI3K. (A) root-mean square deviation (RMSD) of the complex against the initial crystal structure. The blue graph represent RMSD of C alpha and the turquoise one represent RMSD of the side-chain; (B) root-mean square fluctuation (RMSF) of the C alpha residue; (C) The dynamics of hydrogen bond number along MD simulation; (D) the representative of the Tinoscorside A-PI3K complex after 24 ns MD simulation.

https://doi.org/10.1371/journal.pone.0251837.g005
Network pharmacology integrated molecular docking prediction in *Tinospora crispa* Linn. as insulin sensitizer.
Moreover, 7 targets were revealed to have significant protein in insulin resistance pathogenesis and also targeted by \textit{T. crispa} constituents (Fig 6B). The complete \textit{T. crispa} constituents and their targets were shown in S2 Table.

**Discussion**

The present study tried to collect and investigate clues from the known phytoconstituents of \textit{T. crispa} in ameliorating insulin resistance. Investigations were conducted using in silico approaches, including network pharmacology, molecular docking, and molecular dynamics simulation. We elucidated the potential therapeutic network of insulin resistance and intersected this network with the \textit{T. crispa} phytoconstituents potential target network. Both of the networks were complicated networks with 5666 and 267 nodes. The intersection showed us only the protein-related insulin resistance targeted by \textit{T. crispa} constituents. From 267 targets, there were only 22 target proteins that were targeted by \textit{T. crispa} constituents.

KEGG pathways analysis had indicated several signalling pathways, including insulin signalling, PI3K-Akt signalling, MAPK signalling, and TNF signalling pathway, that play vital roles in the therapeutic mechanism of \textit{T. crispa} as insulin sensitizer. Those signalling pathways had close relative to glucose-lowering activity through the regulation of glucose homeostasis, adipolysis, cell proliferation, and antiapoptosis. This showed that \textit{T. crispa}, with its various secondary metabolites, had acted as an insulin sensitizer through different pathways (Fig 7). This finding supports Wink \textit{et al.} statement that the activity of a medicinal plant was due to synergistic interactions of several phytoconstituents [13]. The network pharmacology approach provides an insight into prediction in the mode of action of a medicinal plant comprehensively with multiple target therapies [35]. Network pharmacology analysis also informed that the main phytoconstituents of \textit{T. crispa} as insulin sensitizer were Tinoscorside A, Makisterone C, Borapetoside A, Beta-sitosterol, and Borapetoside B.

Based on former studies, Borapetoside A-C, and E may be the key of \textit{T. crispa} constituents as hypoglycaemic agents [7, 11, 12, 36, 37]. Lam \textit{et al.} reported, the isolated Borapetoside A and C had significantly reduced plasma glucose levels but unable to increase insulin secretion in MIN6 pancreatic beta cells [36]. It indicated that they had other mechanisms of hypoglycemic activity. This study predicts the mechanism of action of Borapetoside A through activation of PPARG and Borapetoside B through inhibition of TNF cytokines to bind to their receptor.

Contrary to previous studies that indicated diterpenoids as active constituents, this study presents Tinoscorside A (N-formylasimilobine 2-O-β-D-glucopyranosyl-(1→2)-β-D-glucopyranoside) as a constituent of \textit{T. crispa} which has the strongest docking binding with some protein targets including PI3K, INSR, and EGFR respectively. Tinoscorsida A was a member of aporphine alkaloid which has never been proven as part of active compounds of \textit{T. crispa} in reducing blood sugar level. This finding indicated that Tinoscorside A could be a potential glucose lowering agent through multiple ways.

The molecular dynamics analysis from the PI3K and Tinoscorside A as the ligand-protein complex with the highest affinity, shows a stable conformation in water solvation under 300 K
temperature and 1 atmospheric pressure. It is in line with the docking analysis result. The formation of 20 hydrogen bonds during the MD simulation indicates that the interaction has a high affinity. Two of these bonds are hydrogen bonds reported in molecular docking. Both bonds involve the amino acids Lys833 and Asp964. These two amino acids are active sites that also interact with native ligands in the crystallographic structure of proteins. In addition to these two residues, eight other amino acids are reported to be involved in the formation of hydrogen bonds. Two of them are also included in active sites that interact with native ligands, namely Tyr867 and Val882. In addition, this study also predicted that *T. crispa* had anti-inflammatory activity through the TNF signalling pathway by inhibiting the binding between TNFA and TNFR.

**Conclusion**

The present study highlights the insulin-sensitizing role of *T. crispa* on insulin resistance pathogenesis by network pharmacology and molecular docking study. The role of *T. crispa* phytocconstituents that served as plant extract with multiple constituents remains still undescribed. Our study provides valuable clues to reveal the prediction of their possible targets and mechanistic pathways of *T. crispa*. The present study highlights the insulin-sensitizing role of *T. crispa* on insulin resistance pathogenesis by network pharmacology and molecular docking study. The role of *T. crispa* phytocconstituents that served as plant extract with multiple constituents remains still undescribed. Our study provides valuable clues to reveal the prediction of their possible targets and mechanistic pathways of *T. crispa*. The result was shown that *T.*
Crispa was a promising plant-based drug to be developed as an insulin sensitizer through multiple pathways, including glucose homeostasis, adipolysis, cell proliferation, and antiapoptosis. However, there are several limitations in the current study, including the limitation of the T. crispa phytoconstituents database that could be more phytoconstituents were not revealed yet and the limitation of the database that serves the activity of the constituents as a single compound neglecting the interaction of the multi-compound itself. Further study on the insulin-sensitizing role of T. crispa and the underlying mechanism are still urgently to be investigated in other methods such as in vitro, in vivo, and clinical study evaluation to verify this in silico study.

Supporting information

S1 Fig. Docking sketch map of best ligand-binding position of T. crispa phytoconstituents and 7 selected target proteins in insulin resistance.

S1 Table. Degree ranking of insulin resistant related targets analyzed by Cytoscape 3.7.2.

S2 Table. 30 T. crispa phytoconstituents and its target proteins [17, 18, 24].

S3 Table. Molecular docking result of T. crispa phytoconstituents to 7 selected target proteins using AutoDock.

Author Contributions

Conceptualization: Ummu Mastna Zuhri, Erni Hernawati Purwaningsih, Nancy Dewi Yuliana.

Data curation: Ummu Mastna Zuhri.

Formal analysis: Ummu Mastna Zuhri, Fadilah Fadilah.

Funding acquisition: Ummu Mastna Zuhri.

Investigation: Ummu Mastna Zuhri, Erni Hernawati Purwaningsih.

Methodology: Ummu Mastna Zuhri, Fadilah Fadilah.

Software: Fadilah Fadilah.

Supervision: Erni Hernawati Purwaningsih, Nancy Dewi Yuliana.

Validation: Ummu Mastna Zuhri, Fadilah Fadilah.

Visualization: Ummu Mastna Zuhri.

Writing – original draft: Ummu Mastna Zuhri, Fadilah Fadilah.

Writing – review & editing: Ummu Mastna Zuhri.

References

1. Pessin JE, Saltiel AR. Signaling pathways in insulin action: Molecular targets of insulin resistance. Vol. 106, Journal of Clinical Investigation. The American Society for Clinical Investigation; 2000. p. 165–9.

2. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: A review of multi-target drugs. Molecules. 2020; 25(8):1–20. https://doi.org/10.3390/molecules25081987 PMID: 32340373
3. Ulrich-Merzenich G, Zelter H, Jobst D, Panek D, Vetter H, Wagner H. Application of the “-Omic-” technologies in phytomedicine. Phytomedicine. 2007; 14(1):70–82. https://doi.org/10.1016/j.phymed.2006.11.011 PMID: 17188482

4. Fukuda N, Yonemitsu M KT. Isolation and structure elucidation of the five new furanoid diterpene glycosides borapetoside C–G. Liebigs Ann der Chemie. 1993; 1993(5):491–5.

5. Lokman EF. The possible mechanisms by which borapetol B stimulates insulin release from rat islets. Int J Med Med Sci. 2014; 47(1):1461–8.

6. Ahmad W, Jantan I, Bukhari SNA. Tinospora crispa (L.) Hook. f. & Thomson: A review of its ethnobotanical, phytochemical, and pharmacological aspects. Front Pharmacol. 2016; 7(MAR):1–19.

7. Ruan CT, Lam SH, Chi TC, Lee SS, Su MJ. Borapetoside C from Tinospora crispa improves insulin sensitivity in diabetic mice. Phytomedicine. 2012; 19(8–9):719–24. https://doi.org/10.1016/j.phymed.2012.03.009 PMID: 22579212

8. Thomas A, Rajesh EK, Kumar DS. The significance of Tinospora crispa in treatment of diabetes mellitus. Phyther Res. 2016; 30(3):357–66. https://doi.org/10.1002/ptr.5559 PMID: 26749336

9. Cachet X, Landrand J, Riffault-Valois L, Bouzidi C, Colas C, Dugay A, et al. Clerodane furanoditerpenoids as the probable cause of toxic hepatitis induced by Tinospora crispa. Sci Rep. 2018; 8(1):1–11.

10. Fukuda N, Yonemitsu M, Kimura T. Studies on the Constituents of the Stems of Tinospora tuberculata BEUMEE. III. New Diterpenoids, Borapetoside B and Borapetol B. Chem Pharm Bull. 1986; 34(7):2868–72.

11. Xu Y, Niu Y, Gao Y, Wang F, Qiu W, Lu Y, et al. Borapetoside E, a clerodane diterpenoid extracted from Tinospora crispa, improves hyperglycemia and hyperlipidemia in high-fat-diet-induced type 2 diabetes mice. J Nat Prod. 2017; 80(8):2319–27. https://doi.org/10.1021/acs.jnatprod.7b00365 PMID: 28742368

12. Ruan CT, Lam SH, Lee SS, Su MJ. Hypoglycemic action of borapetoside A from the plant Tinospora crispa in mice. Phytomedicine. 2013; 20:967–75. https://doi.org/10.1016/j.phymed.2013.02.009 PMID: 23523259

13. Wink M. Modes of Action of Herbal Medicines and Plant Secondary Metabolites. Medicines. 2015; 2(3):251–86. https://doi.org/10.3390/medicines2030251 PMID: 28930211

14. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: Improved access to chemical data. Nucleic Acids Res [Internet]. 2019 Jan 8 [cited 2019 Aug 28]; 47(D1):D1102–9. Available from: https://academic.oup.com/nar/article/47/D1/D1102/5146201 https://doi.org/10.1093/nar/gky1033 PMID: 30371825

15. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem [Internet]. 2009 Dec [cited 2019 Sep 20]; 30(16):2785–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19399780 https://doi.org/10.1002/jcc.21256 PMID: 19399780

16. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-like-ness and medicinal chemistry friendliness of small molecules. Sci Rep [Internet]. 2017 [cited 2019 Oct 28]; 7:42717. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28256516

17. Piñero J, Ramirez-Anguita JM, Saich-Pitarach J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res [Internet]. 2019 Nov 4 [cited 2019 Aug 28]; 46(D1):D1121–7. Available from: http://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkz1021/5611674

18. UniProt Consortium T. UniProt: the universal protein knowledgebase. Nucleic Acids Res [Internet]. 2018 Mar 16 [cited 2019 Apr 24]; 46(5):2699–2699. Available from: https://academic.oup.com/nar/article/46/5/2699/4841658 https://doi.org/10.1093/nar/gky992 PMID: 29423565

19. Usman MS, Kusuma WA, Afendi FM, Heryanto R. Identification of significant proteins associated with diabetes mellitus using network analysis of protein-protein interactions. Comput Eng Appl J. 2019; 8(1):41–52.

20. Li YH, Yu CY, Li XX, Zhang P, Tang J, Yang Q, et al. Therapeutic target database update 2018: Enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res [Internet]. 2017 [cited 2019 Aug 28]; 46(D1):D1121–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29140520

21. Kanoheiwa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019; 47(D1):D590–5. https://doi.org/10.1093/nar/gky962 PMID: 30321428

22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A Software Environment for Integrated Models. Genome Res [Internet]. 2003; 13(22):2498–504. Available from: http://ci.nii.ac.jp/naid/10001910481/ https://doi.org/10.1101/gr.1239303 PMID: 14597658
23. Feller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. Swiss Target Prediction: A web server for target prediction of bioactive small molecules. Nucleic Acids Res [Internet]. 2014 Jul [cited 2019 Dec 6]; 42(Web Server issue):W32–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24792161

24. Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: A web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res [Internet]. 2017 Jul 3 [cited 2019 Aug 28]; 45(W1):W356–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28472422

25. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res [Internet]. 2015 [cited 2019 Jul 3]; 43(Database issue):D447. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383874/ https://doi.org/10.1093/nar/gku1003 PMID: 25352553

26. Berman HM. The protein data bank. Nucleic Acids Res [Internet]. 2000 Jan 1 [cited 2020 Feb 13]; 28(1):235–42. Available from: https://academic.oup.com/article-lookup/doi/10.1093/nar/28.1.235

27. Olson Arthur J. OT. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. NIH Public Access. 2011; 31(2):455–61.

28. Herrndez-Santoyo A, Yair A, Altuzar V, Vivanco-Cid H, Mendoza-Barrer C. Protein-Protein and Protein-Ligand Docking. Protein Eng—Technol Appl. 2013;(May).

29. Fadilah F, Arsianti A, Kusmardi K, Tedjo A. Molecular docking studies of opened-chain analogues of antimycin A3 as caspases inhibitors of apoptosis in colorectal cancer. Asian J Pharm Clin Res. 2016; 9(3):8–10.

30. Laskowski RA, Swindells MB. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model [Internet]. 2011 Oct 24 [cited 2021 Mar 15]; 51(10):2778–86. Available from: https://pubmed.ncbi.nlm.nih.gov/21919503/ https://doi.org/10.1021/ci200227u PMID: 21919503

31. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015 Sep 1; 1–2:19–25.

32. Soteras Gutiérrez I, Lin FY, Vanommeslaeghe K, Lemkul JA, Armacost KA, Brooks CL, et al. Parametrization of halogen bonds in the CHARMM general force field: Improved treatment of ligand–protein interactions. Bioorg Med Chem. 2016 Oct 15; 24(20):4812–25. https://doi.org/10.1016/j.bmc.2016.06.034 PMID: 27353885

33. Yu W, He X, Vanommeslaeghe K, MacKerell AD. Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J Comput Chem [Internet]. 2012 Dec 5 [cited 2021 Aug 18]; 33(31):2451–68. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jcc.23067

34. Jorgensen WL, Chandrashekar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys [Internet]. 1998 Aug 31 [cited 2021 Aug 18]; 79(2):926. Available from: https://aip.scitation.org/doi/abs/10.1063/1.445869

35. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682–90. https://doi.org/10.1038/nchembio.118 PMID: 18936753

36. Lam SH, Ruan CT, Hsieh PH, Su MJ, Lee SS. Hypoglycemic diterpenoids from Tinospora crispa. J Nat Prod. 2012; 75(2):153–9. https://doi.org/10.1021/np200692v PMID: 22283497

37. Lokman EF, Gu HF, Wan Mohamood W, Yusof M, Meng L, Östenson C-G. Anti-diabetic effect of oral borapetol B, isolated from the plant Tinospora crispa, by stimulating insulin resistance. Diabetologia. 2013; 56:1–7.